FOURTH SUPPLEMENTAL INDENTUREFourth Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FOURTH SUPPLEMENTAL INDENTURE, dated as of August 2, 2012 (the “Fourth Supplemental Indenture”), by and among Orapharma, Inc., Orapharma Topco Holdings, Inc. (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
THIRD SUPPLEMENTAL INDENTUREThird Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
THIRD SUPPLEMENTAL INDENTURE, dated as of July 3, 2012 (the "Third Supplemental Indenture"), by and among Valeant Pharmaceuticals Holdings (Barbados) SRL, Valeant International Bermuda, Valeant Laboratories International Bermuda, Valeant Pharmaceuticals Holdings Bermuda, Valeant Pharmaceuticals Nominee Bermuda, Valeant Pharmaceuticals Luxembourg S.à.r.l., Valeant Pharmaceuticals Ireland (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the "Company"), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the "Trustee").
FOURTH SUPPLEMENTAL INDENTUREFourth Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FOURTH SUPPLEMENTAL INDENTURE, dated as of July 3, 2012 (the "Fourth Supplemental Indenture"), by and among Valeant Pharmaceuticals Holdings (Barbados) SRL, Valeant International Bermuda, Valeant Laboratories International Bermuda, Valeant Pharmaceuticals Holdings Bermuda, Valeant Pharmaceuticals Nominee Bermuda, Valeant Pharmaceuticals Luxembourg S.à.r.l., Valeant Pharmaceuticals Ireland (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the "Company"), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the "Trustee").
JOINDER AGREEMENTJoinder Agreement • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This Joinder Agreement is dated as of July 9, 2012 (this “Agreement”), by and among each of the financial institutions set forth on Schedule A annexed hereto (each a “New Term Loan Lender” and collectively the “New Term Loan Lenders”), Valeant Pharmaceuticals International, Inc., a corporation continued under the federal laws of Canada (“Borrower”), the undersigned subsidiaries of Borrower and Goldman Sachs Lending Partners LLC (“GSLP”), as Administrative Agent and Collateral Agent.
FIFTH SUPPLEMENTAL INDENTUREFifth Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FIFTH SUPPLEMENTAL INDENTURE, dated as of August 2, 2012 (the “Fifth Supplemental Indenture”), by and among Orapharma, Inc., Orapharma Topco Holdings, Inc. (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
FIFTH SUPPLEMENTAL INDENTUREFifth Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FIFTH SUPPLEMENTAL INDENTURE, dated as of July 3, 2012 (the "Fifth Supplemental Indenture"), by and among Valeant Pharmaceuticals Holdings (Barbados) SRL, Valeant International Bermuda, Valeant Laboratories International Bermuda, Valeant Pharmaceuticals Holdings Bermuda, Valeant Pharmaceuticals Nominee Bermuda, Valeant Pharmaceuticals Luxembourg S.à.r.l., Valeant Pharmaceuticals Ireland (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the "Company") and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the "Trustee").
FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This First Supplemental Indenture (“Supplemental Indenture”) is made as of June 27, 2012, between Valeant Pharmaceuticals International, Inc. (f/k/a Biovail Corporation), a corporation duly organized and subsisting under the laws of Canada (the “Company”), The Bank of New York Mellon, a New York banking corporation, as Trustee (the "Trustee") and BNY Trust Company of Canada, a Canadian trust corporation, as Co-Trustee (the "Co-Trustee").
SIXTH SUPPLEMENTAL INDENTURESixth Supplemental Indenture • August 3rd, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
SIXTH SUPPLEMENTAL INDENTURE, dated as of August 2, 2012 (the “Sixth Supplemental Indenture”), by and among Orapharma, Inc., Orapharma Topco Holdings, Inc. (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the “Company”) and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
